Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies.
about
Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus.Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE)Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data.The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjectsEvidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitusEfficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study.Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin.Experience with vildagliptin in patients ≥75 years with type 2 diabetes and moderate or severe renal impairment.Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin.A review of gliptins in 2011.Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin.Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes.Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.Drug development from the bench to the pharmacy: with special reference to dipeptidyl peptidase-4 inhibitor development.Pattern of Onset and Risk Factors for Peripheral Oedema During Vildagliptin Use: Analysis from the Vildagliptin Prescription-Event Monitoring Study in England.Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies.Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus.Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man.Effectiveness of adding vildagliptin to the treatment of diabetic patients nonresponsive to the combination of metformin and a sulphonylurea.
P2860
Q33785117-2B9A7705-8C21-4DD5-B1A2-9F6C7DA16E10Q34265490-477C6C8B-EC36-4660-B9AB-420EAF37DE07Q34507122-65B6075C-2A8E-4746-BBB9-4BC43B8ABA21Q34726395-EE098D4A-EC54-4ACF-B98F-7BF912DE74A0Q35166849-448EEF69-98E0-4BB7-8BF9-859F0F3F7EC2Q35997324-197EC252-5F25-40F8-8E5D-9D66AB10FAD8Q36365793-FCB1CA79-627B-4B4D-A6E2-78FB45A37B6BQ36428052-870DFE9F-E88F-4F8E-AC81-E8E9B726BAEFQ37468480-AA0E7A13-5DA9-4ACB-BC9C-DE3B85FAC3C0Q37471910-0F2D468F-750E-459C-B2AC-8C4236B1DD40Q37965612-74AF5CF3-CA1F-4356-B0BF-6BC565FAED2DQ38004088-7701F783-CBBD-4DBB-B24F-0421082D7320Q38083641-F2681F40-E5AA-4698-8B3C-EBB911C38213Q38107347-BBAC440F-2908-422F-9B2B-08B7B5D56C9EQ38126945-D0725BD1-2F41-429A-A2EA-6671B16FDBBDQ38189114-0EEEF526-17CC-4E77-941F-A6116A2DB8C1Q38199526-433C0B08-66BA-414C-99C4-62120D1B8392Q38236774-A9A0A4CD-D244-44E3-9955-5D3DAB4DE491Q38644587-36F5395D-9676-4EBA-88E0-10333FF4E9B4Q38698431-B8D8B2B9-5BC8-4B9D-9454-F25569CBA882Q39480831-518189E2-23D8-429B-866A-4FF23C152BD5Q41966262-5DE97A7B-6C86-46E5-8E26-129A68D8121DQ45350582-FEDDEE56-038D-4E37-A717-6D99680174A7Q47279724-E8EB3BDB-1F73-4BB4-ACCB-8EAF1C210730Q51370472-5FA5B018-9719-4BEC-929E-42708C3300AD
P2860
Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Assessing the general safety a ...... luation of individual studies.
@en
Assessing the general safety a ...... luation of individual studies.
@nl
type
label
Assessing the general safety a ...... luation of individual studies.
@en
Assessing the general safety a ...... luation of individual studies.
@nl
prefLabel
Assessing the general safety a ...... luation of individual studies.
@en
Assessing the general safety a ...... luation of individual studies.
@nl
P2093
P2860
P356
P1476
Assessing the general safety a ...... luation of individual studies.
@en
P2093
Anja Schweizer
James E Foley
Sylvie Dejager
Wolfgang Kothny
P2860
P356
10.2147/VHRM.S16925
P407
P577
2011-02-04T00:00:00Z